Smyth, E. C., Vlachogiannis, G., Hedayat, S., Harbery, A., Hulkki-Wilson, S., Salati, M., Kouvelakis, K., Fernandez-Mateos, J., Cresswell, G. D., Fontana, E., Seidlitz, T., Peckitt, C., Hahne, J. C., Lampis, A., Begum, R., Watkins, D., Rao, S., Starling, N., Waddell, T., Okines, A., Crosby, T., Mansoor, W., Wadsley, J., Middleton, G., Fassan, M., Wotherspoon, A., Braconi, C., Chau, I., Vivanco, I., Sottoriva, A., Stange, D. E., Cunningham, D., & Valeri, N. (2021). eGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. Gut, 70(9), 1632–1641. http://access.bl.uk/ark:/81055/vdc_100144715162.0x000048